温肾化瘀安冲方治疗肾阳虚痰湿血瘀型多囊卵巢综合征的临床研究

Clinical Study on the Effect of Wenshen Huayu Anchong Recipe on Polycystic Ovary Syndrome of Kidney Yang Deficiency, Phlegm-Dampness, and Blood Stasis Pattern

  • 摘要:
    目的 探究温肾化瘀安冲方对肾阳虚痰湿血瘀型多囊卵巢综合征(PCOS)患者自主排卵及月经周期的影响。
    方法 选取2023年4月至2025年2月于江西中医药大学附属医院中医妇科门诊就诊的64例肾阳虚痰湿血瘀型PCOS患者,采用随机数字表法将其分为治疗组与对照组各32例,治疗组服用温肾化瘀安冲方,对照组服用安慰剂,2组疗程均为3个月,治疗后随访1个月。治疗期间治疗组脱落3例、对照组脱落7例。治疗前后评估2组患者中医证候积分、焦虑和抑郁评分(HADS量表)、性功能指数(FSFI)及生活质量(PCOSQ)评分变化情况,观察患者高雄激素血症临床表现(多毛、痤疮、脱发)变化情况,ELISA法检测患者血清性激素水平促卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E2)、泌乳素(PRL)、总睾酮(T),酶法测定患者血清空腹血糖(FBG)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C),CLIA法测定空腹胰岛素(FINS),计算胰岛素抵抗指数(HOMA-IR),治疗期间观察患者不良反应发生情况,治疗后监测患者自主排卵情况。
    结果 治疗3个月后,治疗组患者中医证候积分、月经周期、痤疮评分、LH、LH/FSH、T、FINS、HOMA-IR水平以及PCOSQ、FSFI评分均显著改善(P<0.01),对照组变化不显著。治疗组患者PCOSQ、FSFI评分及月自主排卵率显著高于对照组(P<0.05,P<0.01),中医证候总积分、月经周期、痤疮评分、LH、LH/FSH、T、FINS、HOMA-IR水平均显著低于对照组(P<0.05,P<0.01)。治疗期间,2组均未见明显不良反应。
    结论 温肾化瘀安冲方能有效提高肾阳虚痰湿血瘀型PCOS患者的自主排卵率,同时改善患者血清性激素水平、降低中医证候积分、减轻胰岛素抵抗、提高生活质量,且安全性良好。

     

    Abstract:
    OBJECTIVE To evaluate the effects of Wenshen Huayu Anchong Recipe (WSAR) on spontaneous ovulation and menstrual recovery in patients with polycystic ovary syndrome (PCOS) characterized by kidney yang deficiency, phlegm-dampness, and blood stasis pattern.
    METHODS From April 2023 to February 2025, a total of 64 women with kidney yang deficiency, phlegm-dampness, and blood stasis pattern PCOS who visited the Traditional Chinese Medicine Gynecology Clinic of Jiangxi University of Chinese Medicine Affiliated Hospital were enrolled. Participants were randomly assigned, using a random number table, to the treatment group (n=32) or the control group (n=32). The treatment group received the WSAR, while the control group received a placebo. Both groups were treated for 3 months, with a 1-month follow-up after treatment. During the study, 3 patients in the treatment group and 7 patients in the control group withdrew. Changes in traditional Chinese medicine syndrome scores, anxiety, and depression (HADS), sexual function (FSFI), and quality of life (PCOSQ) were evaluated before and after treatment. Clinical manifestations of hyperandrogenism, including hirsutism, acne, and hair loss, were also assessed. Serum sex hormone levels follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), prolactin (PRL), and total testosterone (T) were measured using ELISA; fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) were measured by enzymatic assay; fasting insulin (FINS) was measured by chemiluminescence immunoassay (CLIA), and the homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Adverse events were monitored during treatment, and spontaneous ovulation was assessed after treatment.
    RESULTS After 3 months of treatment, the treatment group showed significant improvement from baseline in TCM syndrome score, menstrual cycle length, acne score, LH, LH/FSH ratio, T, FINS, HOMA-IR, PCOSQ, and FSFI scores (P<0.01), whereas no significant changes were observed in the control group. Between-group comparisons indicated that the treatment group had a significantly higher monthly spontaneous ovulation rate and significantly higher PCOSQ and FSFI scores than the control group (P<0.05, P<0.01). Additionally, the treatment group had significantly lower TCM syndrome score, menstrual cycle length, acne score, LH, LH/FSH ratio, T, FINS, and HOMA-IR compared with the control group (P<0.05, P<0.01). No obvious adverse reactions were observed in either group during treatment.
    CONCLUSION The WSAR effectively increases the spontaneous ovulation rate in women with PCOS characterized by kidney yang deficiency, phlegm-dampness, and blood stasis pattern, while improving serum hormone levels, reducing traditional Chinese medicine syndrome scores, alleviating insulin resistance, enhancing quality of life, and demonstrating good safety.

     

/

返回文章
返回